Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program - 26 Methods for further developing Rest Quality
- 3Clovis Unified students spend spring break traveling through China
- 4Two IDF officers, civilian face indictment in alleged Gaza aid-truck smuggling scheme
- 5Track down the Ideal Weight reduction Methodology for Your Way of life
- Manageable Living: Eco-Accommodating Decisions for Regular day to day existence
- Israel has clear objectives south of Litani River, but will face difficult choices further north
- Washington state experiences historic flooding as Skagit River hits record high level. See flooding maps, highway closures and forecasts.
- Figure out How to Augment the Advantages of a Web-based Degree
- Figure out How to Alter Your Volvo XC40 for Further developed Solace
- 5 Wellbeing Applications Assist You With remaining Fit
- Several killed in Ukraine and Russia after cross-border attacks
- Dancing through the crackdown: The satirical song soundtracking post-Khamenei Iran
- US healthcare spending soars to over $5 trillion in 2024
